The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
Getinge AB and Databascope Corp.; Analysis of Agreement containing Consent Order to Aid Public Comment
20090243: Glen A. Taylor; Golden Oval Eggs, LLC
0902001 Informal Interpretation
Franciscan Missionaries of Our Lady Health System, Inc./Cappella Healthcare Inc.
King Pharmaceuticals, Inc., and Alpharma Inc., In the Matter of
In late 2008, the Commission issued a consent order to restore competition in the market for oral long-acting opioids (LAOs). The FTC intervened in King Pharmaceutical’s proposed $1.6 billion acquisition of rival drug-maker Alpharma Inc. because the transaction would have joined the two leading producers of morphine sulfate oral LAO’s in the United States, a market which was already highly concentrated and which had annual sales of $4 billion in 2007. In order to maintain competition in the market, the Commission’s consent order requires King to divest its Kadian business to Actavis, a company which already manufactured the drug for King, and which could then produce a generic equivalent of the drug sooner than would have been permitted under King’s patent, which would not have expired until 2010.
Independent Physicians Associates Medical Group, Inc., d/b/a AllCare IPA, In the Matter of
The Commission challenged the conduct of AllCare IPA, alleging that AllCare restrained competition in fee-for-service contracts by fixing prices and other contract terms with payers, engaging in collective negotiations over the terms and conditions of dealing with payers, and preventing group members from negotiating with payers except on terms approved by All Care. The Commission issued a consent order prohibiting All Care from entering into agreements between or among physicians: 1) to negotiate on behalf of any physician with any payer; 2) to refuse to deal, or threaten to refuse to deal, with any payer; 3) to designate the terms, conditions, or requirements upon which any physician deals, or is willing to deal, with any payer, including, but not limited to price terms; 4) not to deal individually with any payer, or not to deal with any payer through any arrangement other than one involving All Care.